News

LARC prolongs interpregnancy intervals but doesn’t cut preterm birth risk
NASHVILLE, TENN. – LARC use reduces short interpregnancy intervals, but does not appear to reduce the risk of...
NASHVILLE, TENN. – LARC use reduces short interpregnancy intervals, but does not appear to reduce the risk of...
All published cohort studies to date have not been able to confirm a significant benefit to combination therapy in UC.
MILAN – There was an “imbalance” in the types of medications prescribed for older and younger patients in the registry, with biologics used more...
MILAN – Improvements in pruritus occurred early with upadacitinib and were pronounced at the highest dose studied, 30 mg daily.
NASHVILLE, TENN. – Communication between patients and HCPs about endometriosis-related dyspareunia is suboptimal, according to results of an...
“The clinical benefits and risk of use in an individual patient must be weighed by the physician.”
This needs to be validated in a large multicenter study.
AMSTERDAM – Patients treated with gilteritinib has superior overall survival, compared with four salvage chemotherapy regimens.
Endoscopists’ self-reported personality traits correlated significantly with their rates of adenoma detection.